A phase I study by Burgess and colleagues investigating the safety of a dry powder formulation of anti-interleukin-13 monoclonal antibody fragment for asthma resulted in one subject testing positive for treatment-associated immunogenicity [42]. This evidence concerns the gene IL13 and asthma.